Atrium Therapeutics, Inc. (RNA) AI Stock Analysis

Atrium Therapeutics, Inc. is a biopharmaceutical company that focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform care for people living with cardiomyopathies. Its development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome, and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. The company also focuses on a pipeline to treat a range of genetic and cardiac diseases. In addition, it maintains research collaboration and license agreements with Bristol-Myers Squibb Company and Eli Lilly and Company.

Atrium Therapeutics generated annual revenue of $9.3M in FY2021, $9.2M in FY2022, $9.6M in FY2023, $10.9M in FY2024, and $18.6M in FY2025, representing a 5-year revenue CAGR of 22.4%. Annual net income moved from -$117.4M in FY2021 to -$322.3M in FY2024, before improving to -$76.7M in FY2025 as R&D expense decreased to $53.8M. For the trailing twelve months ended June 30, 2026, revenue stood at $35.8M with an operating margin of -752.9% and an EPS of -$5.44. In the latest quarter ended June 30, 2026, quarterly revenue fell 21.9% year-over-year.

As of June 30, 2026, Atrium Therapeutics held $264.2M in cash and short-term investments and $1.7M in total debt, resulting in net cash of $262.5M. Total assets were $280.5M and shareholders' equity reached $214.6M, supporting a current ratio of 8.73 and a debt-to-equity ratio of 0.01. During FY2025, operating cash flow was -$41.1M and free cash flow was -$42.6M, with capital expenditures of $1.4M. Over 5 years, the company's share count declined 27.5%.

Atrium Therapeutics closed at $7.67 on October 16, 2026, with a market capitalization of $131.2M and an enterprise value of -$119.9M. The stock trades at a price-to-sales multiple of 3.7x and a price-to-book multiple of 0.7x, compared to a median price-to-sales multiple of 4.1x for its US-listed Healthcare peers. Its EV to revenue stands at 491.0x. Over the 1-year period, the S&P 500 (SPY) returned 16.8%, and over 5 years returned 83.0%, while RNA has traded between a 52-week low of $7.54 and a 52-week high of $16.77.

Wall Street analyst coverage shows 4 Strong Buy ratings, 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $25.00, representing an upside of 225.9% from the last close of $7.67. For the fiscal year ending December 31, 2026, analysts project an EPS of -$3.61 on revenue of $34.4M. For the next fiscal year, 1 analyst estimates revenue of $2.0M and an EPS of -$6.39. The company has beaten EPS estimates in 1 of the last 4 quarters, and the next earnings date is November 12, 2026.

This page is an AI-written research summary of Atrium Therapeutics, Inc. (RNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RNA income statement, RNA balance sheet, RNA key metrics, RNA analyst forecast, RNA chart. See the RNA stock overview for the latest quote and news.